From Custom to On-Demand: Making TCR-Based Cell Therapies Commercially Scalable

• Changing the paradigm, from autologous to allogeneic, from single antigen to multiple activation mechanisms, from custom to on-demand
• Current opportunities and challenges of large-scale TCR-NK cells manufacturing
• Approaches to tackle cost-of-goods and increase patient access

New Data

Speakers:

Emilie Gauthy

CTO

Zelluna Immunotherapy